The clinical significance of cereblon expression in multiple myeloma.

@article{Schuster2014TheCS,
  title={The clinical significance of cereblon expression in multiple myeloma.},
  author={Steven R. Schuster and K. Martin Kort{\"u}m and Yuan Xiao Zhu and Esteban Braggio and Chang-xin Shi and Laura A. Bruins and Jessica E. Schmidt and Greg J. Ahmann and Shaji K Kumar and S Vincent Rajkumar and Joseph Mikhael and Betsy R Laplant and Mia D. Champion and Kristina M Laumann and Bart Barlogie and Rafael Fonseca and P Leif Bergsagel and Martha Q. Lacy and Alexander Stewart},
  journal={Leukemia research},
  year={2014},
  volume={38 1},
  pages={23-8}
}
Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). We demonstrate here that no patient with very low CRBN expression responded to IMiD plus dexamethasone therapy. In 53 refractory MM patients treated with pomalidomide and dexamethasone, CRBN levels predict for decreased response rates and significant differences in PFS (3.0 vs. 8.9 months, p<0.001) and OS (9.1 vs. 27.2 months, p=0.01) (lowest quartile vs. highest three quartiles). While higher CRBN levels can… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…